A new study suggests that macrophage programming is more complex than previously thought.
Inflammatory bowel disease linked to an immune cell run amok
Researchers report that the lasting nature of inflammatory bowel disease may be due to a type of long-lived immune cell that can provoke persistent, damaging inflammation in the intestinal tract.
In one cancer therapy, two halves are safer than a whole
Splitting one type of cancer drug in half and delivering the pieces separately to cancer cells could reduce life-threatening side effects and protect healthy, non-cancerous cells, a new study suggests.
Fat crystals trigger chronic inflammation
A congenital disorder of the fat metabolism can apparently cause chronic hyperreaction of the immune system.
Finding a way to STING tumor growth
The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule. Now, scientists have revealed that STING also activates a separate pathway, one that directly kills tumor-fighting im…
Small change makes cancer vaccine more effective in animal tests
Tweaking the adenovirus spike protein induces a more robust immune reaction for a cancer vaccine against gastric, pancreatic, esophageal and colon malignancies in animal models.
Nasal vaccine against COVID-19 prevents infection in mice
Scientists have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus. The investigators next plan to test the vaccine in nonhu…
Early NK cell-mediated immune response may contribute to severe COVID-19
Researchers may have come one step closer toward understanding how the immune system contributes to severe COVID-19. In a new study, researchers show that so-called natural killer (NK) cells were strongly activated early after SARS-CoV-2 infection but …
Unleashing the immune system’s ‘STING’ against cancer
Scientists have discovered a molecule that can activate a natural immune-boosting protein called STING. The findings mark a key advance in the field of oncology, as the STING protein is known for its strong antitumor properties.
Fighting cancer with rejection-resistant, ‘off-the-shelf’ therapeutic T cells
Researchers are developing ready-to-use, off-the-shelf therapeutic T cells. These are genetically engineered T cells that are manufactured from normal, healthy donors. The cells are expanded and well characterized, and have shown to be effective at kil…